{"success":true,"data":{"pressRelease":{"id":"155501","rtpr_id":"nPn5RLG5Ga-20260929","ticker":"ABBV","exchange":"NYSE","all_tickers":["ABBV"],"title":"AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development","author":"PR Newswire","published_at":"2026-09-29T13:00:06.685Z","article_body":"AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development\nPR Newswire\n\nNORTH CHICAGO, Ill., Sept. 29, 2026\n\n * AbbVie deepens investment in artificial intelligence (AI) by entering into a\nnew collaboration with Valkai to strengthen integrated AI capabilities across\nclinical development\n * AbbVie is committed to integrating AI throughout the drug development journey\nto advance scientific innovation, strengthen operations and improve outcomes\nfor patients\nNORTH CHICAGO, Ill., Sept. 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) is\ninvesting in its artificial intelligence (AI) infrastructure through a new\npartnership with Valkai, a life sciences AI platform designed to help\naccelerate the pace at which scientific innovation reaches patients.\n\nThrough its partnership with Valkai, AbbVie will deploy purpose-built AI\ncapabilities designed to improve efficiency across targeted areas of clinical\nresearch, help teams generate insights more quickly and support opportunities\nto reduce development timelines.\n\nAI plays an important role at AbbVie in advancing scientific innovation,\nstrengthening connected operations and improving how medicines are discovered,\ndeveloped and delivered to patients. Its partnership with Valkai builds on\nAbbVie's strong foundation of applying AI across R&D, helping to further\nscale data-driven insights and innovation.\n\n\"At AbbVie, we are focused on applying AI where it can create meaningful\nimpact for our business and, ultimately, for patients,\" said Nicholas\nDonoghoe, executive vice president, chief business and strategy officer,\nAbbVie. \"As clinical data continues to grow in volume and complexity,\npartnerships like Valkai help us generate insights faster and enable our teams\nto spend more time on the decisions that matter most. By combining advanced AI\ncapabilities with human expertise, we can help bring new medicines to patients\nmore efficiently.\"\n\nAcross AbbVie, AI serves as a critical tool to complement employee insight,\nenabling teams to drive strategic priorities and expedite delivery of\nmedicines to patients, while maintaining a strong commitment to responsible\nand ethical use.\n\n\"We're delighted to partner with AbbVie, combining advanced AI capabilities\nwith deep scientific expertise,\" said Vignesh Rajendran, co-founder and chief\nexecutive officer, Valkai. \"AbbVie's scale, innovation and unwavering focus\non patients make this the kind of partnership that can turn bold ambition into\nmeaningful impact.\"\n\n\"For Clinical Sciences in particular, success depends on the ability to learn\nquickly, adapt intelligently and make confident decisions based on an\never-growing body of evidence,\" said Andrew Campbell, M.D., vice president,\nclinical sciences, AbbVie. \"AI capabilities, like Valkai, have the potential\nto help us reduce time spent on manual processes and focus more attention on\nscientific interpretation and clinical strategy, and ultimately, the insights\nthat can advance medicines for patients.\"\n\nAbout AI@AbbVie\n\nAI@AbbVie is AbbVie's enterprise approach to using artificial intelligence\n(AI) to advance scientific innovation, strengthen business outcomes and\nimprove how medicines are discovered, developed and delivered to patients. AI\nis an important enabler of our mission, helping employees enhance\nproductivity, strengthen decision-making and accelerate progress across\nR&D, operations and other core business functions. Guided by human\nexpertise, responsible governance and a commitment to meaningful impact, we\nare embedding AI across the enterprise to accelerate innovation and help\nimprove patients' lives.\n\nAbout AbbVie\n\nAbbVie's mission is to discover and deliver innovative medicines and solutions\nthat solve serious health issues today and address the medical challenges of\ntomorrow. We strive to have a remarkable impact on people's lives across\nseveral key therapeutic areas including immunology, neuroscience and oncology\n– and products and services in our Allergan Aesthetics portfolio. For more\ninformation about AbbVie, please visit us at www.abbvie.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783263-1&h=195046207&u=http%3A%2F%2Fwww.abbvie.com%2F&a=www.abbvie.com)\n. Follow @abbvie on LinkedIn,\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783263-1&h=1613987183&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fabbvie%2F&a=LinkedIn%2C)\n Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783263-1&h=17917709&u=https%3A%2F%2Fwww.facebook.com%2FAbbVieGlobal%2F&a=Facebook)\n, Instagram\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783263-1&h=1563829547&u=https%3A%2F%2Fwww.instagram.com%2Fabbvie%2F&a=Instagram)\n, X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783263-1&h=45416927&u=https%3A%2F%2Ftwitter.com%2Fabbvie&a=X)\n and YouTube.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783263-1&h=3013413730&u=https%3A%2F%2Fwww.youtube.com%2Fuser%2FAbbVie&a=YouTube.)\n\nAbout Valkai\n\nValkai is the AI operating system for life sciences. Its mission is to\nsignificantly accelerate time to market for the world's most critical\nmedicines. Global Fortune 500 pharma and medtech leaders partner with Valkai\nto enable faster, smarter decision-making. The team hails from pioneering\nresearch and applied AI companies such as OpenAI, Google DeepMind, Sierra and\nGlean.\n\nAbbVie Forward-Looking Statements\n\nSome statements in this news release are, or may be considered,\nforward-looking statements for purposes of the Private Securities Litigation\nReform Act of 1995. The words \"believe,\" \"expect,\" \"anticipate,\" \"project\" and\nsimilar expressions and uses of future or conditional verbs, generally\nidentify forward-looking statements. AbbVie cautions that these\nforward-looking statements are subject to risks and uncertainties that may\ncause actual results to differ materially from those expressed or implied in\nthe forward-looking statements. Such risks and uncertainties include, but are\nnot limited to, challenges to intellectual property, competition from other\nproducts, difficulties inherent in the research and development process,\nadverse litigation or government action, changes to laws and regulations\napplicable to our industry, the impact of global macroeconomic factors, such\nas economic downturns or uncertainty, international conflict, trade disputes\nand tariffs, and other uncertainties and risks associated with global business\noperations. Additional information about the economic, competitive,\ngovernmental, technological and other factors that may affect AbbVie's\noperations is set forth in Item 1A, \"Risk Factors,\" of AbbVie's 2025 Annual\nReport on Form 10-K, which has been filed with the Securities and Exchange\nCommission, as updated by its Quarterly Reports on Form 10-Q and in other\ndocuments that AbbVie subsequently files with the Securities and Exchange\nCommission that update, supplement or supersede such information. AbbVie\nundertakes no obligation, and specifically declines, to release publicly any\nrevisions to forward-looking statements as a result of subsequent events or\ndevelopments, except as required by law.\n Media:                                                             Investors:\n\nCat Langel\nLiz Shea\n\n(708) 508-3524\n(847) 935-2211\n\ncatherine.langel@abbvie.com (mailto:catherine.langel@abbvie.com)\nliz.shea@abbvie.com (mailto:liz.shea@abbvie.com)\n\n \n\nView original\ncontent:https://www.prnewswire.com/news-releases/abbvie-partners-with-valkai-to-apply-advanced-ai-across-targeted-areas-of-clinical-development-302890641.html\n(https://www.prnewswire.com/news-releases/abbvie-partners-with-valkai-to-apply-advanced-ai-across-targeted-areas-of-clinical-development-302890641.html)\n\nSOURCE AbbVie\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn5RLG5Ga-20260929","title":"AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development","author":"PR Newswire","ticker":"ABBV","created":"2026-09-29T13:00:06.685Z","tickers":["ABBV"],"exchange":"NYSE","article_body":"AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development\nPR Newswire\n\nNORTH CHICAGO, Ill., Sept. 29, 2026\n\n * AbbVie deepens investment in artificial intelligence (AI) by entering into a\nnew collaboration with Valkai to strengthen integrated AI capabilities across\nclinical development\n * AbbVie is committed to integrating AI throughout the drug development journey\nto advance scientific innovation, strengthen operations and improve outcomes\nfor patients\nNORTH CHICAGO, Ill., Sept. 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) is\ninvesting in its artificial intelligence (AI) infrastructure through a new\npartnership with Valkai, a life sciences AI platform designed to help\naccelerate the pace at which scientific innovation reaches patients.\n\nThrough its partnership with Valkai, AbbVie will deploy purpose-built AI\ncapabilities designed to improve efficiency across targeted areas of clinical\nresearch, help teams generate insights more quickly and support opportunities\nto reduce development timelines.\n\nAI plays an important role at AbbVie in advancing scientific innovation,\nstrengthening connected operations and improving how medicines are discovered,\ndeveloped and delivered to patients. Its partnership with Valkai builds on\nAbbVie's strong foundation of applying AI across R&D, helping to further\nscale data-driven insights and innovation.\n\n\"At AbbVie, we are focused on applying AI where it can create meaningful\nimpact for our business and, ultimately, for patients,\" said Nicholas\nDonoghoe, executive vice president, chief business and strategy officer,\nAbbVie. \"As clinical data continues to grow in volume and complexity,\npartnerships like Valkai help us generate insights faster and enable our teams\nto spend more time on the decisions that matter most. By combining advanced AI\ncapabilities with human expertise, we can help bring new medicines to patients\nmore efficiently.\"\n\nAcross AbbVie, AI serves as a critical tool to complement employee insight,\nenabling teams to drive strategic priorities and expedite delivery of\nmedicines to patients, while maintaining a strong commitment to responsible\nand ethical use.\n\n\"We're delighted to partner with AbbVie, combining advanced AI capabilities\nwith deep scientific expertise,\" said Vignesh Rajendran, co-founder and chief\nexecutive officer, Valkai. \"AbbVie's scale, innovation and unwavering focus\non patients make this the kind of partnership that can turn bold ambition into\nmeaningful impact.\"\n\n\"For Clinical Sciences in particular, success depends on the ability to learn\nquickly, adapt intelligently and make confident decisions based on an\never-growing body of evidence,\" said Andrew Campbell, M.D., vice president,\nclinical sciences, AbbVie. \"AI capabilities, like Valkai, have the potential\nto help us reduce time spent on manual processes and focus more attention on\nscientific interpretation and clinical strategy, and ultimately, the insights\nthat can advance medicines for patients.\"\n\nAbout AI@AbbVie\n\nAI@AbbVie is AbbVie's enterprise approach to using artificial intelligence\n(AI) to advance scientific innovation, strengthen business outcomes and\nimprove how medicines are discovered, developed and delivered to patients. AI\nis an important enabler of our mission, helping employees enhance\nproductivity, strengthen decision-making and accelerate progress across\nR&D, operations and other core business functions. Guided by human\nexpertise, responsible governance and a commitment to meaningful impact, we\nare embedding AI across the enterprise to accelerate innovation and help\nimprove patients' lives.\n\nAbout AbbVie\n\nAbbVie's mission is to discover and deliver innovative medicines and solutions\nthat solve serious health issues today and address the medical challenges of\ntomorrow. We strive to have a remarkable impact on people's lives across\nseveral key therapeutic areas including immunology, neuroscience and oncology\n– and products and services in our Allergan Aesthetics portfolio. For more\ninformation about AbbVie, please visit us at www.abbvie.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783263-1&h=195046207&u=http%3A%2F%2Fwww.abbvie.com%2F&a=www.abbvie.com)\n. Follow @abbvie on LinkedIn,\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783263-1&h=1613987183&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fabbvie%2F&a=LinkedIn%2C)\n Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783263-1&h=17917709&u=https%3A%2F%2Fwww.facebook.com%2FAbbVieGlobal%2F&a=Facebook)\n, Instagram\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783263-1&h=1563829547&u=https%3A%2F%2Fwww.instagram.com%2Fabbvie%2F&a=Instagram)\n, X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783263-1&h=45416927&u=https%3A%2F%2Ftwitter.com%2Fabbvie&a=X)\n and YouTube.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783263-1&h=3013413730&u=https%3A%2F%2Fwww.youtube.com%2Fuser%2FAbbVie&a=YouTube.)\n\nAbout Valkai\n\nValkai is the AI operating system for life sciences. Its mission is to\nsignificantly accelerate time to market for the world's most critical\nmedicines. Global Fortune 500 pharma and medtech leaders partner with Valkai\nto enable faster, smarter decision-making. The team hails from pioneering\nresearch and applied AI companies such as OpenAI, Google DeepMind, Sierra and\nGlean.\n\nAbbVie Forward-Looking Statements\n\nSome statements in this news release are, or may be considered,\nforward-looking statements for purposes of the Private Securities Litigation\nReform Act of 1995. The words \"believe,\" \"expect,\" \"anticipate,\" \"project\" and\nsimilar expressions and uses of future or conditional verbs, generally\nidentify forward-looking statements. AbbVie cautions that these\nforward-looking statements are subject to risks and uncertainties that may\ncause actual results to differ materially from those expressed or implied in\nthe forward-looking statements. Such risks and uncertainties include, but are\nnot limited to, challenges to intellectual property, competition from other\nproducts, difficulties inherent in the research and development process,\nadverse litigation or government action, changes to laws and regulations\napplicable to our industry, the impact of global macroeconomic factors, such\nas economic downturns or uncertainty, international conflict, trade disputes\nand tariffs, and other uncertainties and risks associated with global business\noperations. Additional information about the economic, competitive,\ngovernmental, technological and other factors that may affect AbbVie's\noperations is set forth in Item 1A, \"Risk Factors,\" of AbbVie's 2025 Annual\nReport on Form 10-K, which has been filed with the Securities and Exchange\nCommission, as updated by its Quarterly Reports on Form 10-Q and in other\ndocuments that AbbVie subsequently files with the Securities and Exchange\nCommission that update, supplement or supersede such information. AbbVie\nundertakes no obligation, and specifically declines, to release publicly any\nrevisions to forward-looking statements as a result of subsequent events or\ndevelopments, except as required by law.\n Media:                                                             Investors:\n\nCat Langel\nLiz Shea\n\n(708) 508-3524\n(847) 935-2211\n\ncatherine.langel@abbvie.com (mailto:catherine.langel@abbvie.com)\nliz.shea@abbvie.com (mailto:liz.shea@abbvie.com)\n\n \n\nView original\ncontent:https://www.prnewswire.com/news-releases/abbvie-partners-with-valkai-to-apply-advanced-ai-across-targeted-areas-of-clinical-development-302890641.html\n(https://www.prnewswire.com/news-releases/abbvie-partners-with-valkai-to-apply-advanced-ai-across-targeted-areas-of-clinical-development-302890641.html)\n\nSOURCE AbbVie\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-29T13:00:08.059075163Z","server_sent_at_ms":1790686808059},"received_at":"2026-09-29T13:00:08.110Z","source_url":"https://www.prnewswire.com/news-releases/abbvie-partners-with-valkai-to-apply-advanced-ai-across-targeted-areas-of-clinical-development-302890641.html"},"analysis":{"id":"144226","press_release_id":"155501","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"AbbVie entered a new partnership with Valkai, a life sciences AI platform, to deploy AI capabilities across targeted areas of clinical development.\n\nThe collaboration aims to improve efficiency in clinical research, speed insight generation, and potentially reduce development timelines, building on AbbVie's existing AI@AbbVie enterprise program.\n\nNo financial terms were disclosed; for a mega-cap like AbbVie this is an operational investment rather than a near-term market-moving event.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"AbbVie deepens its AI-in-R&D push via Valkai partnership -- incremental efficiency story, not a near-term catalyst."},"keyFigures":{},"quotedText":"At AbbVie, we are focused on applying AI where it can create meaningful impact for our business and, ultimately, for patients","namedEntities":{"people":[{"name":"Nicholas Donoghoe","role":"EVP, Chief Business and Strategy Officer, AbbVie"},{"name":"Vignesh Rajendran","role":"Co-founder and CEO, Valkai"},{"name":"Andrew Campbell, M.D.","role":"VP, Clinical Sciences, AbbVie"}],"products":["Valkai AI platform","AI@AbbVie"],"companies":[{"name":"AbbVie","ticker":"ABBV","relationship":"filer/partner"},{"name":"Valkai","relationship":"AI platform partner"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Routine AI-enabled partnership for clinical development tooling with no financial terms, revenue impact, or pipeline milestones disclosed. Mildly positive operational signal for a mega-cap."},"tickerRelevance":{"others":[],"primary":"ABBV"},"globalImportance":20,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mega-cap","eventGravity":"routine AI partnership","financialTermsDisclosed":false}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"AbbVie entered a new partnership with Valkai, a life sciences AI platform, to deploy AI capabilities across targeted areas of clinical development.\n\nThe collaboration aims to improve efficiency in clinical research, speed insight generation, and potentially reduce development timelines, building on AbbVie's existing AI@AbbVie enterprise program.\n\nNo financial terms were disclosed; for a mega-cap like AbbVie this is an operational investment rather than a near-term market-moving event.","key_figures":{},"named_entities":{"people":[{"name":"Nicholas Donoghoe","role":"EVP, Chief Business and Strategy Officer, AbbVie"},{"name":"Vignesh Rajendran","role":"Co-founder and CEO, Valkai"},{"name":"Andrew Campbell, M.D.","role":"VP, Clinical Sciences, AbbVie"}],"products":["Valkai AI platform","AI@AbbVie"],"companies":[{"name":"AbbVie","ticker":"ABBV","relationship":"filer/partner"},{"name":"Valkai","relationship":"AI platform partner"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T13:00:35.480Z","global_importance":20,"audience_relevance":30,"importance_components":{"tickerTier":"mega-cap","eventGravity":"routine AI partnership","financialTermsDisclosed":false}},"durationMs":4546,"modelName":"glm-5.3-flashx"}}